iOnctura Develops Next-Generation PI3K-Delta Inhibitors For Cancer
New Biotech Combining Insights In Fibrosis And Cancer
Emerging Company Profile: Switzerland’s iOnctura is working on PI3K-delta inhibitors and autotaxin inhibitors that have potential in solid tumors and cancer-associated fibrosis.
You may also be interested in...
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
Overall survival data from a follicular lymphoma cohort of its umbrella NHL study indicate umbralisib could match other PI3K delta inhibitors’ efficacy with better safety/tolerability profile.
Handing over $5bn to Galapagos for access to several shots on the inflammation/fibrosis goal, Gilead Sciences CEO Daniel O’Day is still on the prowl for more.